The toxicology of inhaled nitric oxide

Toxicological Sciences

Volumn 59, Issue 1, 2001, Pages 5-16

  Weinberger, Barry ^a,c   Laskin, Debra L ^b   Heck, Diane E ^b   Laskin, Jeffrey D ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CD18 ANTIGEN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DNA; ENDOTHELIN 1; GLUTATHIONE; GUANYLATE CYCLASE; HEMOGLOBIN; HYDROGEN PEROXIDE; INTERLEUKIN 1; INTERLEUKIN 2; IRRITANT AGENT; LUNG SURFACTANT; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITROGEN DIOXIDE; NITROGEN OXIDE; OXYGEN; PEROXYNITRITE; RAF PROTEIN; S NITROSOGLUTATHIONE; SUBSTANCE P; SUPEROXIDE; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASODILATOR AGENT;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CEREBRAL PALSY; CHEMICAL INTERACTION; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG INACTIVATION; DRUG MECHANISM; DRUG SAFETY; EPITHELIUM HYPERPLASIA; HEARING LOSS; HUMAN; INFANT; INFLAMMATION; LUNG BLOOD VESSEL; LUNG EDEMA; METHEMOGLOBINEMIA; MUTAGENICITY; NEWBORN; NEWBORN CARE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHARMACOLOGICAL PARAMETERS; PREMATURITY; PULMONARY HYPERTENSION; RAT; REGULATORY MECHANISM; RESPIRATORY DISTRESS; THROMBOCYTE AGGREGATION; TOXICOLOGY; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; CYCLIC GMP; DNA DAMAGE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INHALATION EXPOSURE; NITRIC OXIDE; PULMONARY CIRCULATION; VASODILATOR AGENTS;

ANIMALIA;

EID: 0035150710     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/59.1.5     Document Type: Article

References (138)

1. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation
2. Inhaled nitric oxide does not influence bleeding time or platelet function in healthy volunteers
3. Blockade of endogenous nitric oxide production results in moderate hypertension, reducing sympathetic activity and shortening bleeding time in healthy volunteers
4. Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-cyclic-monophosphate levels in various tissue preparations
5. Mutagenicity of nitric oxide and its inhibition by antioxidants
6. Rebound pulmonary hypertension after inhalation of nitric oxide
7. The effect of nitric oxide and peroxynitrite on apoptosis in human polymorphonuclear leukocytes
8. Pre-treatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury
9. Nitric oxide attenuates interleukin-2-induced lung injury
10. Technical considerations for inhaled nitric oxide therapy: Time response to nitric oxide dosing changes and formation of nitrogen dioxide
11. S-nitrosylation of proteins
12. Nitric oxide and mitochondrial respiration
13. Negative feedback regulation of endothelial cell function by nitric oxide
14. Recommendations for occupational safety and health standards
15. Adenovirus-mediated gene transfer of a cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP
16. Interaction of surfactant mixtures with reactive oxygen and nitrogen species
17. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn
18. Life-threatening effects of discontinuing inhaled nitric oxide in children
19. Effects of exogenous nitric oxide on neutrophil oxidative function and viability
20. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: A randomized, double-masked, placebo-controlled, dose-response multi-center study. The I-NO/PPHN study group
21. Safety of withdrawing inhaled nitric oxide in persistent pulmonary hypertension of the newborn
22. Right ventricular size is acutely decreased by inhaled nitric oxide in newborns with pulmonary hypertension
23. Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension
24. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase-II trial
25. Independent and combined effects of prolonged inhaled nitric oxide and oxygen on lung inflammation in newborn piglets
26. DNA damage by peroxynitrite characterized with DNA repair enzymes
27. 2
28. Nitric oxide therapy for the newborn infant
29. Exogenous nitric oxide enhances neutrophil cell death and DNA fragmentation
30. Safety guidelines for use of nitric oxide
31. Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal humans
32. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: A randomized controlled trial
33. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene
34. Free-radical chemistry of nitric oxide: Looking at the dark side
35. Near fatal pulmonary hypertension after surgical repair of congenital diaphragmatic hernia: Successful use of inhaled nitric oxide
36. Inhaled nitric oxide, clinical rationale and applications
37. Nitric-oxide donor decreases neutrophil adhesion in both lung and peritoneum during peritonitis
38. Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation
39. Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury
40. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates
41. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
42. The kinetics and equilibria of the reactions of nitric oxide with sheep hemoglobin
43. The oxyhemoglobin reaction of nitric oxide
44. Effects of higher oxides of nitrogen on the anesthetized dog
45. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo
46. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers
47. Nitric oxide: I. Physiological chemistry of nitric oxide and its metabolites: Implications in inflammation
48. Inhaled NO prevents IL-1 induced neutrophil accumulation and associated acute edema in isolated rat lungs
49. Nitric oxide-induced down-regulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells
50. Nitric oxide regulation of superoxide-dependent lung injury: Oxidant-protective actions of endogenously produced and exogenously administered nitric oxide
51. Concurrent generation of nitric oxide and superoxide damages surfactant protein A
52. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants
53. A mechanism of nitric oxide-induced surfactant dysfunction
54. Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure
55. Surfactant protein-A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid
56. Surfactant dysfunction after inhalation of nitric oxide
57. Antiproliferative effects of NO and ANP in cultured human airway smooth muscle
58. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP
59. Nitric oxide regulates interleukin 1 bioactivity released from murine macrophages
60. Pulmonary changes in animals exposed to nitrogen dioxide, effects of acute exposures
61. Synergistic effects of high-frequency ventilation and inhaled nitric oxide in the treatment of hypoxemic respiratory failure in infancy
62. Inhaled nitric oxide in premature infants-a meta-analysis
63. Methaemoglobinemia after inhalation of nitric oxide for treatment of hydrochlorthiazide-induced pulmonary oedema
64. Induction of the cyclin-dependent kinase inhibitor p21 (Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells
65. Induction of mutations and chromosome aberrations in lung cells following in vivo exposure of rats to nitrogen oxides
66. Nitrovasodilator repletion increases TNF-alpha-induced pulmonary edema
67. Role of endogenous nitric oxide in airway microvascular leakage induced by inflammatory mediators
68. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties
69. Activation of poly(ADP-ribose) synthetases mediates hyperpermeability induced by peroxynitrite in human intestinal epithelial cells
70. Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxic lung injury. Role of cyclic guanosine 5′-monophosphate
71. Low dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn
72. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease
73. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: A randomized controlled trial
74. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide
75. Nitric oxide-releasing oxatriazole derivatives inhibit human lymphocyte proliferation by a cyclic GMP-independent mechanism
76. Circulating methemoglobin and nitrite/nitrate concentrations as indicators of nitric oxide overproduction in critically ill children with septic shock
77. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide
78. Molecular and biochemical features of poly(ADP-ribose) metabolism
79. Biology of nitric oxide signaling
80. Intracellular cyclic GMP receptor proteins
81. Production of nitrogen dioxide during nitric oxide therapy using the Servo Ventilator 300 during volume-controlled ventilation
82. A kinetic study on functional impairment of nitric oxide-exposed rat erythrocytes
83. Inhaled nitric oxide injures the pulmonary surfactant system of lambs in vivo
84. Nitric oxide attenuates lung endothelial injury caused by sublethal hyperoxia in rats
85. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Preemie NO Collaborative Group
86. Endogenous nitric oxide modifies antigen-induced microvascular leakage in sensitized guinea pig airways
87. Nitric oxide-dependent induction of glutathione synthesis through increased expression of gamma-glutamylcysteine synthetase
88. 2 as markers of altered surfactant metabolism
89. Regulation of cytosolic guanylyl cyclase by nitric oxide: The NO-cyclic GMP signal transduction system
90. Methaemoglobinemia after inhalation of nitric oxide in infant with pulmonary hypertension
91. NIOSH criteria for a recommended standard for occupational exposure to oxides of nitrogen (nitrogen dioxide and nitric oxide)
92. Nitric oxide increases the survival of rats with a high oxygen exposure
93. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure
94. Inhaled nitric oxide in term and near-term infants: Neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group
95. Inhaled nitric oxide modulates leukocyte kinetics in the mesenteric venules of endotoxemic rats
96. DNA damage and mutation in human cells exposed to nitric oxide in vitro
97. Results of the French prospective multicentre randomized double-blind, placebo-controlled trial on inhaled nitric oxide in ARDS
98. Induction and stabilization of I-κB-α by nitric oxide mediates inhibition of NF-κB
99. Inhaled nitric oxide: More than a selective pulmonary vasodilator
100. Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis
101. Kinetics of methemoglobin formation and elimination as a function of inhaled nitric oxide concentration and minute ventilation
102. Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation
103. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups
104. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group
105. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn
106. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat
107. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension
108. Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes
109. Peroxynitrite causes DNA nicks in plasmid pBR322
110. Inhibition of MIP-1 alpha-induced human neutrophil and monocyte chemotactic activity by reactive oxygen and nitrogen metabolites
111. Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression
112. Formation of nitrogen dioxide from nitric oxide and their measurement in clinically relevant circumstances
113. Vascular biosynthesis of nitric oxide: Effect on hemostasis and fibrinolysis
114. Blood analysis of rabbits exposed to nitrogen monoxide
115. Effect of nitric oxide synthase inhibition on bleeding time in humans
116. Nitrogen dioxide formation during inhaled nitric oxide therapy
117. Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine
118. Blood-flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient
119. Nitric oxide and nitrogen dioxide as inducers of acute pulmonary injury when inhaled at relatively high concentrations for brief periods
120. Open randomized controlled trial of inhaled nitric oxide and early dexamethasone in high-risk, pre-term infants
121. DNA strand breakage and activation of poly-ADP ribosyl-transferase: A cytotoxic pathway triggered by peroxynitrite
122. Endothelial dysfunction in endotoxic shock: Importance of the activation of poly(ADP-ribose) synthetases by peroxynitrite
123. DNA damage induced by peroxynitrite: Subsequent biological effects
124. Peroxynitrite causes energy depletion and increases permeability via activation of poly-ADP ribose synthetases in pulmonary epithelial cells
125. Nitric oxide and nitrogen dioxide concentrations during in vitro high-frequency ventilation
126. Acute Exposure Guideline Levels (AEGLs) for Nitric Oxide
127. Nitric oxide increases tumor necrosis factor production in differentiated U937 cells by decreasing cyclic AMP
128. Inhaled nitric oxide primes lung macrophages to produce reactive oxygen and nitrogen intermediates
129. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension
130. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn
131. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease
132. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors
133. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide
134. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation
135. Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination
136. Role of superoxide and nitric oxide in platelet activating factor-induced acute lung injury, hypotension, and mortality in rats
137. Methaemoglobin production in normal adults inhaling low concentrations of nitric oxide
138. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting activation of epidermal growth factor signaling pathway